A Phase III Clinical Trial Evaluating DCVax®-Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme
The primary objective of this study is to evaluate progression-free-survival in patients receiving DCVax-Brain to treat GBM.
Neuroscience - Brain Tumor
Charles Cobbs, MD
- 18 to 70 years
- Life expectancy greater than 8 weeks
- History of malignancy
- History of immuodeficiency or autoimmune disease